MiR-195/miR-497 Regulate Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer

Overview

Journal J Breast Cancer

Date 2019 Jan 5

PMID 30607158

Citations 27

Authors

Lianzhou Yang

Yuchen Cai

Dongsheng Zhang

Jian Sun

Chenyu Xu

Wenli Zhao

Wenqi Jiang

Chunhua Pan

Affiliations

Soon will be listed here.

Abstract

Purpose: Immune suppression is common in patients with advanced breast cancer but the mechanisms underlying this phenomenon have not been sufficiently studied. In this study, we aimed to identify B7 family members that were able to predict the immune status of patients, and which may serve as potential targets for the treatment of breast cancer. We also aimed to identify microRNAs that may regulate the expression of B7 family members.

Methods: The Cancer Genome Atlas data from 1,092 patients with breast cancer, including gene expression, microRNA expression and survival data, were used for statistical and survival analyses. Polymerase chain reaction and Western blot were used to measure messenger RNA and protein expression, respectively. Luciferase assay was used to investigate direct microRNA target.

Results: Bioinformatic analysis predicted that microRNA (miR)-93, miR-195, miR-497, and miR-340 are potential regulators of the immune evasion of breast cancer cells, and that they exert this function by targeting , , and . We chose for further investigations. We found that miR-195, miR-497, and expression levels were inversely correlated in MDA-MB-231 cells, and miR-195 and miR-497 expressions mimic inhibited expression . Mechanistic investigations demonstrated that miR-195 and miR-497 directly target 3' untranslated region.

Conclusion: Our data indicated that the level of B7 family members can predict the prognosis of breast cancer patients, and miR-195/miR-497 regulate expression in triple negative breast cancer. This regulation may further influence tumor progression and the immune tolerance mechanism in breast cancer and may be able to predict the effect of immunotherapy on patients.

Citing Articles

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.

Jin M, Fang J, Peng J, Wang X, Xing P, Jia K Mol Cancer. 2024; 23(1):266.

PMID: 39614285 PMC: 11605969. DOI: 10.1186/s12943-024-02176-8.

Epigenetic modification in radiotherapy and immunotherapy for cancers.

Hung S, Lee M, Chiou W, Liu D, Yu C, Chen L Tzu Chi Med J. 2024; 36(4):396-406.

PMID: 39421493 PMC: 11483092. DOI: 10.4103/tcmj.tcmj_3_24.

Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.

Abdul Manap A, Wisham A, Wong F, Ahmad Najmi H, Ng Z, Diba R Front Cell Dev Biol. 2024; 12:1390704.

PMID: 38726321 PMC: 11079208. DOI: 10.3389/fcell.2024.1390704.

Novel microRNAs modulating ecto-5'-nucleotidase expression.

Kordass T, Chao T, Osen W, Eichmuller S Front Immunol. 2023; 14:1199374.

PMID: 37409119 PMC: 10318900. DOI: 10.3389/fimmu.2023.1199374.

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.

Kumar S, Chatterjee M, Ghosh P, Ganguly K, Basu M, Ghosh M Genes Dis. 2023; 10(4):1318-1350.

PMID: 37397537 PMC: 10311058. DOI: 10.1016/j.gendis.2022.07.024.

References

Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8(6):467-77. DOI: 10.1038/nri2326. View

Xu H, Cheung I, Guo H, Cheung N . MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009; 69(15):6275-81. PMC: 2719680. DOI: 10.1158/0008-5472.CAN-08-4517. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A . B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg. 2010; 252(6):1044-51. DOI: 10.1097/SLA.0b013e3181f1939d. View

Wu L, Chen Z, Zhang J, Xing Y . Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells. J Huazhong Univ Sci Technolog Med Sci. 2012; 32(4):601-606. DOI: 10.1007/s11596-012-1004-8. View

Budczies J, Klauschen F, Sinn B, Gyorffy B, Schmitt W, Darb-Esfahani S . Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7(12):e51862. PMC: 3522617. DOI: 10.1371/journal.pone.0051862. View

Yang P, Tang R, Zhu J, Zou L, Wu R, Zhou H . A functional variant at miR-24 binding site in B7-H2 alters susceptibility to gastric cancer in a Chinese Han population. Mol Immunol. 2013; 56(1-2):98-103. DOI: 10.1016/j.molimm.2013.04.010. View

Faget J, Sisirak V, Blay J, Caux C, Bendriss-Vermare N, Menetrier-Caux C . ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. Oncoimmunology. 2013; 2(3):e23185. PMC: 3661154. DOI: 10.4161/onci.23185. View

Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y . MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014; 75(4):348-53. DOI: 10.1016/j.humimm.2014.01.006. View

10.

Muenst S, Schaerli A, Gao F, Daster S, Trella E, Droeser R . Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014; 146(1):15-24. PMC: 4180714. DOI: 10.1007/s10549-014-2988-5. View

11.

Fan L, Strasser-Weippl K, Li J, St Louis J, Finkelstein D, Yu K . Breast cancer in China. Lancet Oncol. 2014; 15(7):e279-89. DOI: 10.1016/S1470-2045(13)70567-9. View

12.

Wu R, Li F, Zhu J, Tang R, Qi Q, Zhou X . A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population. Med Oncol. 2014; 31(8):60. DOI: 10.1007/s12032-014-0060-2. View

13.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

14.

Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5:5241. PMC: 4212319. DOI: 10.1038/ncomms6241. View

15.

Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y . Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2014; 27(3):443-52. DOI: 10.1016/j.cellsig.2014.12.003. View

16.

Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M . B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6(5):3452-61. PMC: 4413666. DOI: 10.18632/oncotarget.3097. View

17.

Gibson J . Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol. 2015; 16(6):e264. DOI: 10.1016/S1470-2045(15)70208-1. View

18.

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

19.

Guo W, Tan W, Liu S, Huang X, Lin J, Liang R . MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol. 2015; 36(11):9049-57. DOI: 10.1007/s13277-015-3644-3. View

20.

Yuan S, Li H, Yang M, Zha H, Sun H, Li X . High intensity focused ultrasound enhances anti-tumor immunity by inhibiting the negative regulatory effect of miR-134 on CD86 in a murine melanoma model. Oncotarget. 2015; 6(35):37626-37. PMC: 4741953. DOI: 10.18632/oncotarget.5285. View